Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab vs Placebo as Adjuvant Therapy in High-risk Muscle-invasive Bladder Cancer (IMvigor011)
NCT04660344Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- May 2021
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies
- Countries
- 23
01
Overview
A Phase 3 trial of atezolizumab in muscle-invasive bladder cancer (MIBC), sponsored by Roche. Started May 2021; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT04660344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04660344.